2014

BioAlliance Pharma Announces Shareholders’ Meeting and Approval of all resolutions

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, announces that it held its Shareholders’ meeting at its headquarters on April 8, 2014 and has adopted all the resolutions recommended by its Board of Directors. Among other decisions, the Shareholders’ meeting has confirmed the Director’s mandate for annual re-election…read more →

BioAlliance Pharma répond aux conditions d’éligibilité du dispositif PEA-PME

BioAlliance Pharma SA, Société d’innovation spécialisée dans le développement de médicaments visant des pathologies orphelines en cancérologie, annonce son éligibilité au dispositif fiscal PEA-PME. BioAlliance Pharma, dont les titres sont cotés sur le NYSE Euronext compartiment C (Code ISIN : FR0010095596), confirme répondre à l’ensemble des critères d’éligibilité au PEA-PME conformément au Décret n° 2014-283 du 4 mars 2014 (moins…read more →

BioAlliance Pharma signs a new licensing agreement with Daewoong Pharmaceutical Co., Ltd. for Sitavig®’s commercialization in South Korea

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announces an exclusive supply and license agreement for Sitavig® (Acyclovir Lauriad®) with Daewoong Pharmaceutical Co., Ltd. for commercialization rights in South Korea. Moreover, Daewoong will be in charge of registering Sitavig® in South Korea. Under this agreement, BioAlliance Pharma…read more →

BioAlliance Pharma provides an update on its partnerships for Loramyc®/Oravig®

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, updates on Loramyc®/Oravig® development programs by its Asian partners and on its US partnership. In the United States, after one year of marketing by American partner Vestiq Pharmaceutical, the sales performance of Oravig® was not meeting the expectations. Consequently, BioAlliance…read more →

BioAlliance Pharma collaborates with Penn Pharma on the industrial development of Validive®

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, announced today an agreement with Penn Pharma to manufacture Validive®, currently in a late phase II trial for the prevention and treatment of severe oral mucositis induced by radiotherapy and/or chemotherapy in head and neck cancer patients. Penn Pharma is…read more →

Sitavig® Licensing Strategy: Execution of licensing agreement with Innocutis for North America and Positive opinion from French and German Health Authorities for Marketing Authorization

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced major advancements in the licensing strategy of Sitavig® (acyclovir Lauriad®) for the treatment of recurrent labial herpes, with the execution of a licensing agreement with Innocutis Holding LLC to commercialize Sitavig® in North America. In Europe, the Company received a positive…read more →

BioAlliance Pharma provides updates on its major achievements and reports 2013 consolidated financial results

2013: Significant progress on key strategic programs • Livatag® phase III (ReLive): European expansion and authorization from the FDA to perform the trial in the US • Validive®: Fast track designation granted, allowing future accelerated review by the FDA • NDA granted for Sitavig® by FDA. For the second time, BioAlliance succeeds to register a drug in the US 2014:…read more →

Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today a major strengthening of the patent protection for its product Livatag® (doxorubicine Trandrug™), currently in phase III clinical trial in primary liver cancer (ReLive trial). The European Patent Office has issued a new patent family for Livatag® protecting its specific…read more →

BioAlliance Pharma’s partner, Sosei, announces a partnership with FUJIFILM Pharma for commercialization rights for Loramyc® in Japan

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced that its Japanese partner, Sosei Co. Ltd, has entered into a distribution agreement with FUJIFILM Pharma Co., Ltd, for commercialization rights in Japan for Loramyc® (miconazole Lauriad®) mucoadhesive tablet. In May 2011, BioAlliance Pharma signed a licensing agreement with Sosei to…read more →

FDA grants Validive® (clonidine Lauriad®) with a Fast Track Designation for the prevention and treatment of oral mucositis induced by anticancer treatments

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology, announced today that Validive® (clonidine Lauriad®) received a Fast Track designation from the U.S. Food and Drug Administration (FDA) for the prevention and treatment of oral mucositis induced by radiotherapy and/or chemotherapy in cancer patients. The Fast Track procedure is designed to facilitate…read more →